YE

Earth Science Tech, Inc Initiates Up-Listing Process to the OTCQB Exchange with the OTC Markets Group, Inc.

Retrieved on: 
Thursday, July 6, 2023
OTC, YE, OTCQB, Health

Becoming an OTCQB fully reporting company will increase the Company’s value, visibility, and transparency.

Key Points: 
  • Becoming an OTCQB fully reporting company will increase the Company’s value, visibility, and transparency.
  • Given where we are today, it is appropriate for the company to up-list.
  • To me, this shows the commitment to transparency and execution of the entire team.
  • Up-listing to OTCQB, is another step in the direction of becoming a great company.” Stated ETST’s CEO and Chairman of the Board of Directors, Giorgio R. Saumat.

SEQUANA MEDICAL SUCCESSFULLY RAISES EUR 15.78 MILLION IN AN EQUITY PLACEMENT

Retrieved on: 
Tuesday, April 25, 2023
Overload, BY, AFRICA, Interest, Heart failure, Liver disease, Partner, Cancer, Pie, Falls, AMERICA, Underwriting, Trial of the century, KBC, EUR, Quality management system, DSR, Prospectus, PMA, Patient, Offering, Ascites, YE, Van Lanschot Kempen, FDA, Security (finance), Pharmaceutical industry, Life insurance, Holding company, Music, Brussels Stock Exchange

Ian Crosbie, Chief Executive Officer of Sequana Medical, commented: "We are very pleased to announce the closing of this financing round, despite challenging market conditions.

Key Points: 
  • Ian Crosbie, Chief Executive Officer of Sequana Medical, commented: "We are very pleased to announce the closing of this financing round, despite challenging market conditions.
  • EUR 15.2 million of which EUR 12.2 million has been spent up to YE 2022 with the remainder to be attributed over 2023/2024;
    (ii)   Preparing the PMA (Pre-Market Approval) filing and review, with planned submission to the FDA in H2 2023.
  • EUR 9.9 million of which EUR 5.4 million has been spent up to YE 2022 with the remainder to be attributed over 2023/2024.
  • EUR 2.2 million of which EUR 0.7 million has been spent up to YE 2022 with the remainder to be spent from 2023 until 2025.

SEQUANA MEDICAL LAUNCHES EQUITY PLACEMENT AND AMENDS CERTAIN EXISTING LOAN AGREEMENTS

Retrieved on: 
Monday, April 24, 2023
CMS, Marketing, Partner, Medicare, DSR, PMA, Patient, Van Lanschot Kempen, RED, Heart failure, Pie, Underwriting, Limited, Offering, Ascites, FDA, BY, CFR, Interest, Centers for Medicare & Medicaid Services, Cancer, AMERICA, Quality management system, Overload, AFRICA, Liver disease, Person, Trial of the century, KBC, EUR, Prospectus, Brussels Stock Exchange, YE, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Life insurance, Bank, Holding company, Music, Security (finance), Credit, Management, Republic

EUR 9.9 million of which EUR 5.4 million has been spent up to YE 2022 with the remainder to be attributed over 2023/2024.

Key Points: 
  • EUR 9.9 million of which EUR 5.4 million has been spent up to YE 2022 with the remainder to be attributed over 2023/2024.
  • (i)   Interest expense and a partial repayment of the loan facility with Kreos Capital (total loan cost of EUR 2.4 million up to Q1 2024), resulting from amendments to the above loan agreement, subject to certain conditions;
    (ii)   General corporate and working capital purposes.
  • The Offering shall be structured as a private placement of new shares and subscription rights via an accelerated bookbuilding, which will commence immediately.
  • Trading in Sequana Medical shares on Euronext Brussels will be suspended during the bookbuilding period.

Flow Capital Announces 2022 Annual Audited Financial Results

Retrieved on: 
Wednesday, March 29, 2023
Exercise, Interest, Book value, Sale, FW, Royalty payment, Investment, Yoy, Growth, YE, YTD, Security (finance), Cryptocurrency

TORONTO, Ontario, March 28, 2023 (GLOBE NEWSWIRE) -- Flow Capital Corp. (TSXV: FW) (“Flow Capital” and “Company”), a leading provider of flexible growth capital and alternative debt solutions, announces its audited financial and operating results for the three-months (“Q4 2022”) and year ended December 31, 2022 (“YE 2022”).

Key Points: 
  • TORONTO, Ontario, March 28, 2023 (GLOBE NEWSWIRE) -- Flow Capital Corp. (TSXV: FW) (“Flow Capital” and “Company”), a leading provider of flexible growth capital and alternative debt solutions, announces its audited financial and operating results for the three-months (“Q4 2022”) and year ended December 31, 2022 (“YE 2022”).
  • Revenue from Royalties and Interest of $2.26M in Q4 2022; Fiscal 2022 Royalty and Interest revenue of $7.8M; YoY growth of 28%
    Book value of approximately $1.22 per share; YoY growth of 63%.
  • IFRS Net income of $9.1M in Q4 2022, compared to $2.26M in Q4 2021.
  • $882K in Q4 2022, compared to $313K in Q4 2021; Adjusted Recurring Free Cash Flow1 of over $2.9 million YTD; YoY growth of 76%.

Flow Capital Announces 2022 Annual Audited Financial Results

Retrieved on: 
Wednesday, March 29, 2023
Exercise, Interest, Book value, Sale, FW, Royalty payment, Investment, Yoy, Growth, YE, YTD, Security (finance), Cryptocurrency

TORONTO, Ontario, March 28, 2023 (GLOBE NEWSWIRE) -- Flow Capital Corp. (TSXV: FW) (“Flow Capital” and “Company”), a leading provider of flexible growth capital and alternative debt solutions, announces its audited financial and operating results for the three-months (“Q4 2022”) and year ended December 31, 2022 (“YE 2022”).

Key Points: 
  • TORONTO, Ontario, March 28, 2023 (GLOBE NEWSWIRE) -- Flow Capital Corp. (TSXV: FW) (“Flow Capital” and “Company”), a leading provider of flexible growth capital and alternative debt solutions, announces its audited financial and operating results for the three-months (“Q4 2022”) and year ended December 31, 2022 (“YE 2022”).
  • Revenue from Royalties and Interest of $2.26M in Q4 2022; Fiscal 2022 Royalty and Interest revenue of $7.8M; YoY growth of 28%
    Book value of approximately $1.22 per share; YoY growth of 63%.
  • IFRS Net income of $9.1M in Q4 2022, compared to $2.26M in Q4 2021.
  • $882K in Q4 2022, compared to $313K in Q4 2021; Adjusted Recurring Free Cash Flow1 of over $2.9 million YTD; YoY growth of 76%.

Keller Williams Expands to Germany

Retrieved on: 
Thursday, February 16, 2023
REIT, Other Construction & Property, Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, Momentum, Williams, Government, United Kingdom, Deutsche Bank, YE, KWW, Funding Circle, Keller Williams, Region, KW, CRM, Nicolaus, Small business, Growth, J. P. Morgan, Renewable energy, Property management, Drug

Keller Williams (KW), the world's largest real estate franchise by agent count, announces continued robust worldwide growth and expansion into Germany.

Key Points: 
  • Keller Williams (KW), the world's largest real estate franchise by agent count, announces continued robust worldwide growth and expansion into Germany.
  • “Ten years since the launch of KWW, our continued rapid pace of multinational growth showcases how entrepreneurs globally are thriving at Keller Williams,” said William E. Soteroff, president of KWW.
  • “And, today we’re excited to announce our expansion into Germany, our 18th master franchise in Europe.”
    Led by Regional Operating Principal Swen Nicolaus, KW Germany is currently initializing operations.
  • “With Keller Williams, the spotlight is always on the entrepreneurial realtor.”
    As of Jan. 31, KW has 160 market centers and 4,806 agents across Europe.

DSG Global Inc. Files its Form 10-Q and Announces Financial Results for Q3 2022 Including Revenue Growth of 186% from Q3 2021

Retrieved on: 
Tuesday, November 15, 2022
Software, COVID-19, Result, Financial condition report, Conversation, Golf, History, Wi-Fi, Form 10-Q, Risk, Club Car, Transport, EV, Village, Annual report, Sumathi Best Television Current Reporting Award, VTS, Analysis, Security (finance), Sport utility vehicle, Vantage, News, TAG, TEXT, YE, OTCQB, GPS, Fleet management, Satellite navigation device, Video game, Ridesharing company, Risk management, Online shopping, Infinity

Sales for Q3 2022 totaled $1,425,673 compared to $498,380 for Q3 2021, an increase of $927,293 or 186%.

Key Points: 
  • Sales for Q3 2022 totaled $1,425,673 compared to $498,380 for Q3 2021, an increase of $927,293 or 186%.
  • As of September 30, 2022, the Company had additional signed contracts which it is working to fulfill by YE.
  • Gross profit for Q3 2022 totaled $472,832, compared to $271,928 for Q2 2021, an increase of $200,904 or 74%.
  • Gross profit for Q3 2022 totaled $1,090,122 compared to $822,026 for Q3 2021, an increase of $268,096 or 32.61%.

Caribou Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 8, 2022
GLOBE, Private Securities Litigation Reform Act, IND, History, LL, Rachel Haurwitz, U.S. Securities and Exchange Commission, FDA, MM, Genome, Annual general meeting, YE, Nasdaq, CRISPR/Cpf1, Food, Follicular lymphoma, Accounting, Research, Risk, American Society of Hematology, Acute myeloid leukemia, Society, Lymphatic system, G&A, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Efficiency, DNA, RNA, Annual report, Patient, Safety, ODD, CRISPR, AML, Clinical trial, Lymphoma, Growth, Security (finance), AbbVie, Insurance, ASH, Phenotype, Congress, Reindeer, Medical device, Cryptocurrency, Fine chemical, Pharmaceutical industry, Vaccine, Sewing, Leukemia

BERKELEY, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the third quarter of 2022 and provided a business update.

Key Points: 
  • CB-020: Caribou expects to announce target selection for CB-020, an iPSC-derived CAR-NK cell therapy for solid tumors, in Q4 2022.
  • Additionally, Caribou expects to disclose armoring strategies under development for its CAR-NK cell platform in Q4 2022.
  • Caribou Biosciences and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.
  • Except as required by law, Caribou undertakes no obligation to update publicly any forward-looking statements for any reason.

MERKLE STANDARD REACHES 3.1 EH/s OF TOTAL OPERATING CAPACITY, EXPANDS ITS FOOTPRINT TO THE EAST COAST

Retrieved on: 
Monday, October 3, 2022
Bitcoin, Total, Mining, ASIC, Application-specific integrated circuit, Miner, CEO, YE, Multimedia, Carbon, S19, Company, View, Cryptocurrency

Merkle Standard Reaches 3.1 EH/s of Total Operating Capacity, Expands its Footprint to the East Coast.

Key Points: 
  • Merkle Standard Reaches 3.1 EH/s of Total Operating Capacity, Expands its Footprint to the East Coast.
  • Merkle Standard prides itself as one of the industry's most efficient miners and continues to prioritize cutting-edge technology.
  • In February of 2022, Merkle Standard announced a 500 MW joint venture with BITMAIN, the world's leading ASIC manufacturer.
  • To learn more about Merkle Standard, visit www.merklestandard.com
    View original content to download multimedia: https://www.prnewswire.com/news-releases/merkle-standard-reaches-3-1-ehs...

DGAP-News: TAG Immobilien AG: Strong operating business performance in the second quarter of 2022 for TAG Immobilien AG across all metrics. LTV reduced below 45% through capital increase in July 2022

Retrieved on: 
Tuesday, August 23, 2022
Renting, YE, Trust, City, TAG, LTV, Total, EUR, CFO, FFO, Housing, EPRA, Group, James, Hoyer, Newcomer & Smiljanich, P.A., Acquisition, Security (finance), Renewable energy, Film, Beauty salon

TAG Immobilien AG: Strong operating business performance in the second quarter of 2022 for TAG Immobilien AG across all metrics.

Key Points: 
  • TAG Immobilien AG: Strong operating business performance in the second quarter of 2022 for TAG Immobilien AG across all metrics.
  • LTV reduced below 45% through capital increase in July 2022
    The issuer is solely responsible for the content of this announcement.
  • Strong operating business performance in the second quarter of 2022 for TAG Immobilien AG across all metrics.
  • After the reporting date, the vacancy rate was further reduced and is currently only around 5.0% in August 2022.